866-997-4948(US-Canada Toll Free)

Benign Prostatic Hyperplasia (BPH) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Published By :

GlobalData

Published Date : Dec 2010

Category :

Therapeutic Area

No. of Pages : 52 Pages


GlobalData, the industry analysis specialist, has released its new report, “Benign Prostatic Hyperplasia (BPH) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global benign prostatic hyperplasia therapeutics market. The report identifies the key trends shaping and driving the global benign prostatic hyperplasia therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global benign prostatic hyperplasia therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. 

GlobalData’s analysis suggests that the global Benign Prostatic Hyperplasia (BPH) therapeutic market was worth $5.2 billion in 2009. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 3.6% for the next eight years to reach $6.9 billion by 2017. This growth rate is primarily attributable to the strong current treatment options, as well as a strong pipeline rich in first-in-class molecules. This growth will be further supported by the high incidence rate of the disease and the introduction of first-in-class and me-too therapies with improved clinical benefits. 

Scope

The report provides information on the key drivers and challenges of the benign prostatic hyperplasia therapeutics market. Its scope includes:

  • Annualized global benign prostatic hyperplasia therapeutics market revenues data from 2001 to 2009, forecast for eight years to 2017.
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under different mechanisms of actions, which include PDE5, type II 5a-reductase inhibitors, muscarinic acetylcholine receptor antagonist, GnRH receptor antagonists, SARM and PSA protease binder.
  • Analysis of the current and future competition in the global benign prostatic hyperplasia therapeutics market. Key market players covered are Eli Lilly and Company, Nippon Shinyaku Co. Ltd, Nymox Pharmaceutical Corporation and Protox Therapeutics Inc
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the benign prostatic hyperplasia therapeutics therapeutics market.
Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global benign prostatic hyperplasia therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global benign prostatic hyperplasia therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What’s the next big thing in the global benign prostatic hyperplasia therapeutics market landscape? - Identify, understand and capitalize.
Table of Contents

1 Table of Contents

1.1 List of Tables
1.2 List of Figures

2 Benign Prostatic Hyperplasia: Introduction
2.1 Overview
2.2 GlobalData Pipeline Report Guidance

3 Benign Prostatic Hyperplasia Therapeutic Market: Market Characterization
3.1 Benign Hyperplasia Therapeutics Market size
3.2 Benign Prostatic Hyperplasia Therapeutics Market Forecast and CAGR
3.3 Drivers and Barriers for the Benign Prostatic Hyperplasia Therapeutics Market
3.3.1 Drivers for the Benign Prostatic Hyperplasia Therapeutics Market
3.3.2 Barriers for the Benign Prostatic Hyperplasia Therapeutic Market
3.4 Opportunity and Unmet Need
3.5 Key Takeaway

4 Benign Prostatic Hyperplasia Therapeutics Market - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles of the Major Marketed Products in the Benign Prostatic Hyperplasia Therapeutic Market
4.3.1 Duodart (Fixed Dose Combination of Avodart and tamsulosin)
4.3.1.1 Overview
4.3.1.2 Efficacy
4.3.1.3 Safety
4.3.1.4 Pricing
4.3.1.5 Clinical study details
4.3.2 Alfuzosin (Xatral, Uroxatral)
4.3.2.1 Overview
4.3.2.2 Efficacy
4.3.2.3 Safety
4.3.2.4 Pricing
4.3.2.5 Clinical study details
4.3.3 Tamsulosin (Flomax, Harnal)
4.3.3.1 Overview
4.3.3.2 Efficacy
4.3.3.3 Safety
4.3.3.4 Pricing
4.3.3.5 Clinical study details
4.3.4 Terazosin (Hytrin)
4.3.4.1 Overview
4.3.4.2 Efficacy
4.3.4.3 Safety
4.3.4.4 Pricing
4.3.4.5 Clinical study details
4.3.5 Finasteride (Proscar)
4.3.5.1 Overview
4.3.5.2 Efficacy
4.3.5.3 Safety
4.3.5.4 Pricing
4.3.5.5 Clinical study details
4.3.6 Doxazosin (Cardura, Cardura XL)
4.3.6.1 Overview
4.3.6.2 Efficacy
4.3.6.3 Safety
4.3.6.4 Pricing
4.3.6.5 Clinical study details
4.3.7 Dutasteride (Avodart)
4.3.7.1 Overview
4.3.7.2 Efficacy
4.3.7.3 Safety
4.3.7.4 Pricing
4.3.7.5 Clinical study details
4.3.8 Silodosin (Rapaflo / Urief)
4.3.8.1 Overview
4.3.8.2 Efficacy
4.3.8.3 Safety
4.3.8.4 Pricing
4.3.8.5 Clinical Study Details
4.4 Key Takeaway

5 Benign Prostatic Hyperplasia Therapeutics Market: Pipeline Assessment

5.1 Overview
5.2 Strategic Pipeline Assessment
5.2.1 Technology Trends Analytic Framework
5.3 Benign Prostatic Hyperplasia Therapeutics - Promising Drugs Under Clinical Development
5.4 Molecule Profile for Promising Drugs Under Clinical Development
5.4.1 Cialis (Tadalafil)
5.4.1.1 Overview
5.4.1.2 Efficacy
5.4.1.3 Safety
5.4.1.4 Clinical study details
5.4.2 NX-1207
5.4.2.1 Overview
5.4.2.2 Efficacy
5.4.2.3 Safety
5.4.2.4 Clinical study details
5.4.3 PRX302
5.4.3.1 Overview
5.4.3.2 Efficacy
5.4.3.3 Safety
5.4.3.4 Clinical study details
5.5 Benign Prostatic Hyperplasia Therapeutics Market - Clinical Pipeline by Mechanism of Action
5.6 Benign Prostatic Hyperplasia Therapeutics Pipeline - Pipeline by Clinical Phases of Development
5.6.1 Benign Prostatic Hyperplasia Therapeutics - Regulatory Filing and Phase III Clinical Pipeline
5.6.2 Benign Prostatic Hyperplasia Therapeutics - Phase II Clinical Pipeline
5.6.3 Benign Prostatic Hyperplasia Therapeutics - Phase I Clinical Pipeline
5.6.4 Benign Prostatic Hyperplasia Therapeutics - Preclinical and Discovery Pipeline
5.7 Key Takeaway

6 Benign Prostatic Hyperplasia Therapeutic Market: Implications for Future Market Competition

7 Benign Prostatic Hyperplasia Therapeutic Market: Future Players in the Benign Prostatic Hyperplasia Therapeutic Market
7.1 Introduction
7.2 Eli Lilly and Company
7.2.1 Company Overview
7.2.2 Business Description
7.2.3 Genitourinary Pipeline Product Portfolio
7.2.4 Benign Prostatic Hyperplasia Therapeutic Product Portfolio
7.2.4.1 Cialis (Tadalafil)
7.2.4.2 Overview
7.2.4.3 Efficacy
7.2.4.4 Safety
7.2.4.5 Clinical Study Details
7.2.4.6 Phase II Results
7.3 Nippon Shinyaku Co. Ltd
7.3.1 Company Overview
7.3.2 Business Description
7.3.3 Genitourinary Pipeline Product Portfolio
7.3.4 Benign Prostatic Hyperplasia Therapeutic Product Portfolio
7.4 Nymox Pharmaceutical Corporation
7.4.1 Company Overview
7.4.2 Business Description
7.4.3 Genitourinary Pipeline Product Portfolio
7.4.4 Benign Prostatic Hyperplasia Therapeutic Product Portfolio
7.4.4.1 NX-1207
7.4.4.2 Overview
7.4.4.3 Efficacy
7.4.4.4 Safety
7.4.4.5 Clinical Study Details
7.5 Protox Therapeutics, Inc.
7.5.1 Company Overview
7.5.2 Business Description
7.5.3 Genitourinary Pipeline Product Portfolio
7.5.4 Benign Prostatic Hyperplasia Therapeutic Product Portfolio
7.5.4.1 PRX302
7.5.4.2 Overview
7.5.4.3 Efficacy
7.5.4.4 Safety
7.5.4.5 Clinical Study Details
7.6 Light Sciences Oncology, Inc.
7.6.1 Company Overview
7.6.2 Business Description
7.6.3 Genitourinary Pipeline Product Portfolio
7.6.4 Benign Prostatic Hyperplasia Therapeutic Product Portfolio
7.6.4.1 Aptocine
7.6.4.2 Overview
7.6.4.3 Efficacy
7.6.4.4 Safety
7.6.4.5 Clinical Trial

8 Benign Prostatic Hyperplasia Therapeutic Market - Appendix

8.1 Market Definition
8.2 Abbreviations
8.2.1 Coverage
8.2.2 Secondary Research
8.2.3 Forecasting
8.2.3.1 Epidemiology-based Forecasting
8.2.4 Primary Research
8.2.5 Expert Panels
8.3 Contact Us
8.4 Disclaimer
8.5 Sources

List of Table


Table 1: BPH Therapeutics Market, Global, Revenue ($m), 20012009 10
Table 2: BPH Therapeutics Market, Global, Market Forecast ($m), 20092017 10
Table 3: Major Marketed Products Comparison in the BPH Therapeutics Market, 2010 25
Table 4: BPH Therapeutics Most Promising Drugs Under Clinical Development, 2010 29
Table 5: BPH Therapeutics Regulatory Phase III Clinical Pipeline, 2010 34
Table 6: BPH Therapeutics Phase II Clinical Pipeline, 2010 35
Table 7: Benign Prostatic Hyperplasia Therapeutics Phase I Clinical Pipeline, 2010 35
Table 8: Benign Prostatic Hyperplasia Therapeutics Preclinical and Discovery Pipeline, 2010 35
Table 9: Eli Lilly and Company Genitourinary Pipeline, 2010 39
Table 10: Nippon Shinyaku Co. Ltd Genitourinary Pipeline, 2010 41
Table 11: Nymox Pharmaceutical Corporation Genitourinary Pipeline, 2010 42
Table 12: Protox Therapeutics, Inc. Genitourinary Pipeline, 2010 44
Table 13: Light Sciences Oncology, Inc. Genitourinary Pipeline, 2010 45

List of Chart


Figure 1: BPH Therapeutics Market, Global, Revenue ($m), 20012009 9
Figure 2: BPH Therapeutics Market, Global, Market Forecast ($m), 20092017 10
Figure 3: Opportunity and Unmet Need in the BPH Therapeutics Market 13
Figure 4: Strategic Competitor Assessment of the Marketed Products for BPH Therapeutics, 2010 15
Figure 5: Technology Trends Analytic Framework of the BPH Therapeutics Pipeline, 2010 28
Figure 6: Technology Trends Analytic Framework of the BPH Therapeutics Pipeline Description, 2010 28
Figure 7: BPH Therapeutics Clinical Pipeline by Mechanism of Action, 2010 33
Figure 8: BPH Therapeutics Pipeline by Phase of Clinical Development, 2010 34
Figure 9: Implications for Future Market Competition in the BPH Therapeutics Market, 2010 37
Figure 10: Benign Prostatic Hyperplasia Therapeutics Market Clinical Pipeline by Company (Number of Molecules), 2010 38
Figure 11: GlobalData Market Forecasting Model 50

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *